6-Ethoxydihydrosanguinarine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

6-Ethoxydihydrosanguinarine 显示人血液乙酰胆碱酯酶 (HuAChE) 和人血浆丁酰胆碱酯酶 (HuBuChE) 抑制活性，IC50 值分别为 0.83 +/- 0.04 microM 和 4.20 +/- 0.19 microM。

6-Ethoxydihydrosanguinarine shows human blood acetylcholinesterase (HuAChE) and human plasma butyrylcholinesterase (HuBuChE) inhibitory activity, with IC50 values of 0.83 +/- 0.04 microM and 4.20 +/- 0.19 microM, respectively.

Ethoxysanguinarine inhibits cells vialibity with IC50 of 9.37 μM (SW480 cells); 7.19μM (HCT116 cells); 6.55 μM (HT69 cells); 3.57 μM (SW620 cells).Ethoxysanguinarine (3 μM or 5 μM, 24 h) down-regulates phospho-Akt, decreases CIP2A/PP2A/Akt pathway expression in the SW620 and HT29 cells.Ethoxysanguinarine (3 μM or 5 μM, 24 h) increases the PP2A activity and inhibits phosphorylation of CIP2A downstream molecule protein kinase B.Ethoxysanguinarine (1-3 μM or 4.5-5 μM, 24 h) decreases CIP2A transcription (protein level) and induces CIP2A proteolysis in the SW620 and HT29 cells. Cell Viability Assay Cell Line:Colorectal cancer (CRC) cell lines: SW620, SW480, HT29 and HCT116 Concentration:0.5-12 μM Incubation Time:24 hours Result:Inhibited the viability of CRC cells with IC50 of 3.57-9.37 μM.Apoptosis Analysis Cell Line:Colorectal cancer (CRC) cell lines: SW620, HT29 Concentration:0-3 μM or 0-5 μM, respectively Incubation Time:24 hours Result:Induced caspase-dependent apoptosis in colorectal cancer (CRC) cells.

Ethoxysanguinarine (0.5 mg/kg; s.c.; 5 times per week; 4 weeks) represses colorectal cancer (CRC) xenograft tumors growth in mice. Animal Model:Nude immunodeficient mice (5-week-old, weighing about 16 g)Dosage:0.5 mg/kg Administration:Subcutaneous injection; 5 times per week for 4 weeks Result:Exhibited antitumor effects without reduce the body weight of the mice.

——

Endocrinology/Hormones

AChR

HuAChE

——

——

28342-31-6

377.39

C22H19NO5

>98% (HPLC)

In Vitro:?DMSO : 60 mg/mL (158.99 mM)

CN1C2=C3C(C=C4OCOC4=C3)=CC=C2C5=C(C6=C(OCO6)C=C5)C1OCC

——

(-20℃)

With Ice Pack

≥ 2 years